AC Immune SA and Piramal Imaging, a division of Piramal Enterprises Ltd., announced today that they have entered into an exclusive worldwide license agreement for the research, development and ...
PI-2620 is in Phase 3 development in Alzheimer’s disease by AC Immune’s partner, LMI This Fast Track designation applies across Alzheimer’s disease, progressive supranuclear palsy, and corticobasal ...
LAUSANNE, Switzerland - AC Immune SA (NASDAQ:ACIU), a biopharmaceutical company specializing in neurodegenerative diseases, has received Fast Track Designation from the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback